Targazyme, Inc.

About Targazyme, Inc.

This author has not yet filled in any details.
So far Targazyme, Inc. has created 19 blog entries.

TargaZyme, Inc. Receives Orphan Drug Designation To TZ101 For Use With Regulatory T Cells To Prevent & Reduce The Severity Of Graft Versus Host Disease In Patients Eligible For Hematologic Stem Cell Transplantation

SAN DIEGO, February 10, 2015: Orphan designation provides 7-year post approval marketing exclusivity, tax credits and elimination of FDA prescription drug user fees Targazyme Inc., a clinical-stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for stem cell transplantation, immunotherapy, gene therapy and regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TZ101 to prevent and reduce the severity and incidence of graft vs. host disease (GVHD) in patients eligible for hematologic stem cell transplant. GVHD is a serious, life-threating complication of stem cell transplantation.  Orphan drug status

By |February 17th, 2015|Categories: Press Releases|0 Comments

TargaZyme, Inc. Announces Receipt of An SBIR Award from the National Institute of Dental and Craniofacial Research

TargaZyme, Inc. Announces  Receipt of An SBIR Award from the National Institute of Dental and Craniofacial Research For the Development of TZ 101 Treated Mesenchymal Stem Cells for Treatment of Oral Mucositis San Diego, CA August 26, 2014 – TargaZyme, Inc. (formerly America Stem Cell, Inc.)  a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund  the  development of genetically-modified mesenchymal stem cells treated with Targazyme’s lead product, TZ101 for treatment of oral mucositis. This SBIR award is from the

By |August 27th, 2014|Categories: Press Releases|0 Comments

TargaZyme, Inc. Awarded SBIR Grant from National Eye Institute

TargaZyme, Inc. Awarded SBIR Grant from National Eye Institute San Antonio, TX July 31, 2014 -- TargaZyme, Inc. (formerly America Stem Cell, Inc.) a clinical- stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund its program for a novel cell-based restorative approach to treat diabetes- related retinopathy. This SBIR award is from the National Eye Institute and Targazyme will be collaborating with Dr. Maria Grant from the Department of Ophthalmology at Indiana University School of Medicine to conduct the research. Retinal

By |August 1st, 2014|Categories: Press Releases|0 Comments

TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board

TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board San Diego, CA  June 3, 2014  -- TargaZyme, Inc. (formerly America Stem Cell, Inc. or the “Company”), a clinical-stage biopharmaceutical company developing enzyme platform technologies/products  to improve efficacy outcomes for cell therapy and cancer immunotherapy,  announced today that it has appointed Christopher Calhoun to its Business Advisory Board. Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer. Lynnet Koh, Chairman & CEO of  TargaZyme, Inc., stated “Mr. Calhoun is a visionary entrepreuneur, a proven public company CEO with a successful track record

Targazyme, Inc. Appoints Dr. Mark W. Schwartz to Board of Directors

San Antonio, TX   March 4, 2014  -- Targazyme, Inc. (formerly America Stem Cell, Inc., the “Company”) announced today that is has appointed Mark W. Schwartz, Ph.D. to the Company’s Board of Directors. Dr. Schwartz will serve the Company as an independent member of the Board.    As an independent director, Dr. Schwartz will assist in the Company in further enhancing its corporate governance protocols and oversight committees, as well as assist management in setting and meeting corporate goals, including establishing key strategic partnerships and providing guidance on long-term capital raising in both private and public markets.  With the appointment of Dr.

By |March 4th, 2014|Categories: Press Releases|0 Comments

Targazyme, Inc. Selected to Present at 2014 BIO CEO & Investor Conference

San Antonio, TX   February 5, 2014  -- Targazyme, Inc. (formerly America Stem Cell, Inc.) has been selected to present at the 2014 BIO CEO & Investor Conference being held in New York City on February 10-11, 2014.  The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Targazyme is a privately held clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy.  Targazyme will be presenting in the oncology track for private companies to some of the most influential members

By |February 5th, 2014|Categories: Press Releases|0 Comments

America Stem Cell, Inc to Present at 12th Annual BIO Investor Forum. BIO Investor Forum to be held October 8-9 in San Francisco, Calif.

San Francisco, CA, October 1, 2013 – America Stem Cell, Inc (ASC) announced that Lynnet Koh, CEO will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, Calif. "ASC was founded with the vision to make stem cell transplantation and cell therapy safer and more efficacious for patients. The profound efficacy and safety results from our current Phase I/IIa trial at M.D. Anderson Cancer Center with

By |October 1st, 2013|Categories: Press Releases|0 Comments

AMERICA STEM CELL, INC. RECEIVES FDA CLEARANCE FOR ITS MULTI-CENTER NATIONWIDE TRIAL

AMERICA STEM CELL, INC. RECEIVES FDA CLEARANCE FOR ITS MULTI-CENTER NATIONWIDE TRIAL San Antonio, TX  SEPTEMBER 4, 2012. America Stem Cell, Inc. (ASC) announced today it has received clearance from FDA for its Phase I/IIa nationwide multi-center dual-umbilical cord transplantation study evaluating ASC-101 in in patients with hematologic malignancies and myelodysplastic syndrome. ASC-101 is currently undergoing evaluation in a single-center study at The University of Texas MD Anderson Cancer.  To date, 12 patients have been enrolled in the study with 9 patients evaluable.  On the basis of data obtained in the single-center study, FDA has given approval to proceed with

By |September 4th, 2012|Categories: Press Releases|0 Comments

AMERICA STEM CELL, INC. initiates a Phase I/II trial of ASC-101 in patients with hematologic malignancies undergoing dual-cord transplantation

AMERICA STEM CELL, INC. initiates a Phase I/II trial of ASC-101 in patients with hematologic malignancies undergoing dual-cord transplantation Novel enzyme technology to enhance stem cell homing and engraftment for improved clinical outcomes for cancer patients San Antonio, TX, August 27, 2012. America Stem Cell, Inc. announced today the initiation of a single-center study at The University of Texas MD Anderson Cancer Center evaluating ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies. “There is a significant unmet medical need to improve stem cell engraftment into bone marrow for patients undergoing umbilical cord transplantation, and America Stem Cell is

By |August 27th, 2012|Categories: Press Releases|0 Comments